Autocrine Production of PDGF Stimulated by the Tenascin-C-Derived Peptide TNIIIA2 Induces Hyper-Proliferation in Glioblastoma Cells.
Animals
Autocrine Communication
Brain Neoplasms
/ metabolism
Cell Line, Tumor
Cell Movement
Cell Proliferation
Cells, Cultured
Fibroblasts
/ metabolism
Glioblastoma
/ metabolism
Humans
Male
Matrix Metalloproteinase 2
/ metabolism
Mice
Neurons
/ drug effects
Peptide Fragments
/ chemistry
Platelet-Derived Growth Factor
/ metabolism
Rats
Rats, Wistar
Receptors, Platelet-Derived Growth Factor
/ metabolism
Tenascin
/ chemistry
PDGF
PDGF receptor
glioblastoma
tenascin-C
β1-integrin
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
28 Jun 2019
28 Jun 2019
Historique:
received:
18
05
2019
revised:
20
06
2019
accepted:
25
06
2019
entrez:
3
7
2019
pubmed:
3
7
2019
medline:
18
12
2019
Statut:
epublish
Résumé
Expression level of tenascin-C is closely correlated to poor prognosis in glioblastoma patients, while the substantial role of tenascin-C responsible for aggressive progression in glioblastoma cells has not been clarified. We previously found that peptide TNIIIA2, which is derived from the tumor-associated tenascin-C variants, has the ability to promote cell adhesion by activating β1-integrins. Our recent study demonstrated that potentiated activation of integrin α5β1 by TNIIIA2 causes not only a dysregulated proliferation in a platelet-derived growth factor (PDGF)-dependent manner, but also disseminative migration in glioblastoma cells. Here, we show that TNIIIA2 enhances the proliferation in glioblastoma cells expressing PDGF-receptorβ, even without exogenous PDGF. Mechanistically, TNIIIA2 induced upregulated expression of PDGF, which in turn stimulated the expression of tenascin-C, a parental molecule of TNIIIA2. Moreover, in glioblastoma cells and rat brain-derived fibroblasts, tenascin-C upregulated matrix metalloproteinase-2, which has the potential to release TNIIIA2 from tenascin-C. Thus, it was shown that autocrine production of PDGF triggered by TNIIIA2 functions to continuously generate a functional amount of PDGF through a positive spiral loop, which might contribute to hyper-proliferation in glioblastoma cells. TNIIIA2 also enhanced
Identifiants
pubmed: 31261783
pii: ijms20133183
doi: 10.3390/ijms20133183
pmc: PMC6651645
pii:
doi:
Substances chimiques
Peptide Fragments
0
Platelet-Derived Growth Factor
0
Tenascin
0
Receptors, Platelet-Derived Growth Factor
EC 2.7.10.1
Matrix Metalloproteinase 2
EC 3.4.24.24
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Science and Technology Agency
ID : 23590090
Références
Int J Cancer. 1999 Aug 12;82(4):477-83
pubmed: 10404058
Am J Pathol. 2000 May;156(5):1489-98
pubmed: 10793060
Clin Cancer Res. 2000 Oct;6(10):3944-8
pubmed: 11051242
Nat Rev Cancer. 2002 Mar;2(3):161-74
pubmed: 11990853
Cancer Res. 2002 Jul 1;62(13):3729-35
pubmed: 12097282
Clin Cancer Res. 2002 Jul;8(7):2455-62
pubmed: 12114453
Cancer Res. 1992 Jun 1;52(11):3213-9
pubmed: 1317261
Eur J Biochem. 1992 Apr 15;205(2):545-9
pubmed: 1374029
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Nat Rev Cancer. 2006 Oct;6(10):764-75
pubmed: 16990854
J Biol Chem. 2007 Nov 30;282(48):34929-37
pubmed: 17901052
Leukemia. 2008 Feb;22(2):353-60
pubmed: 17972943
Cancer Res. 2007 Nov 1;67(21):10241-51
pubmed: 17974965
PLoS One. 2009 Nov 13;4(11):e7752
pubmed: 19915670
Cell Mol Life Sci. 2011 Oct;68(19):3175-99
pubmed: 21818551
Ups J Med Sci. 2012 May;117(2):99-112
pubmed: 22509804
Cancer Res. 2012 Jul 15;72(14):3463-70
pubmed: 22593187
Cancer Biol Ther. 2013 Apr;14(4):287-94
pubmed: 23358475
Cancer Res. 2013 May 15;73(10):3145-54
pubmed: 23644530
Cell Tissue Res. 2013 Nov;354(2):409-30
pubmed: 23963648
J Cell Sci. 2013 Sep 1;126(Pt 17):3799-804
pubmed: 23970415
Cancer Res. 2014 Jan 1;74(1):3-7
pubmed: 24327727
N Engl J Med. 2014 Feb 20;370(8):699-708
pubmed: 24552317
N Engl J Med. 2014 Feb 20;370(8):709-22
pubmed: 24552318
J Biol Chem. 2014 Jun 20;289(25):17699-708
pubmed: 24808173
Cancer Cell. 2014 Aug 11;26(2):288-300
pubmed: 25117714
Cell Adh Migr. 2015;9(1-2):48-82
pubmed: 25482829
Cell Adh Migr. 2015;9(1-2):131-40
pubmed: 25695402
Front Pharmacol. 2015 Nov 24;6:279
pubmed: 26635609
PLoS One. 2016 Sep 13;11(9):e0162525
pubmed: 27622612
Exp Mol Pathol. 2017 Apr;102(2):262-267
pubmed: 28223108
Proc Natl Acad Sci U S A. 2017 Jul 11;114(28):E5625-E5634
pubmed: 28652369
Mol Cancer Ther. 2019 Jun 12;:null
pubmed: 31189613
Thromb Res. 1982 Jul 1;27(1):1-14
pubmed: 6812233
J Biol Chem. 1995 Apr 14;270(15):8650-4
pubmed: 7536739
J Biol Chem. 1997 Mar 28;272(13):8133-6
pubmed: 9079625
Clin Cancer Res. 1995 Sep;1(9):1035-41
pubmed: 9816077